Scarica l'app Stockscreener
23.24
4.95%
-1.21
Dopo l'orario di chiusura:
23.00
-0.24
-1.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNGX Giù?
Forum
Previsione
Precedente Chiudi:
$24.45
Aprire:
$25.09
Volume 24 ore:
5.25M
Relative Volume:
2.01
Capitalizzazione di mercato:
$3.92B
Reddito:
$56.99M
Utile/perdita netta:
$-107.23M
Rapporto P/E:
-28.34
EPS:
-0.8199
Flusso di cassa netto:
$-142.55M
1 W Prestazione:
-6.74%
1M Prestazione:
+4.12%
6M Prestazione:
+7.44%
1 anno Prestazione:
+202.21%
Intervallo 1D:
$23.09
$25.09
Intervallo di 1 settimana:
$23.09
$25.43
Portata 52W:
$6.69
$34.39
Tango Therapeutics Inc Stock (TNGX) Company Profile
Nome
Tango Therapeutics Inc
Settore
Industria
Telefono
(857) 320-4900
Indirizzo
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
23.24 | 4.20B | 56.99M | -107.23M | -142.55M | -0.8199 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-02 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-23 | Iniziato | Mizuho | Outperform |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-17 | Iniziato | Jefferies | Buy |
| 2024-04-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Iniziato | Piper Sandler | Overweight |
| 2023-12-08 | Iniziato | B. Riley Securities | Buy |
| 2022-10-20 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Tango Therapeutics Inc Borsa (TNGX) Ultime notizie
Tango Therapeutics (TNGX) Receives a Buy from Guggenheim - theglobeandmail.com
Tango Therapeutics principal accounting officer sells $198k in stock By Investing.com - Investing.com Nigeria
Form 4 Tango Therapeutics Inc For: 24 September By Investing.com - Investing.com Australia
Tango Therapeutics principal accounting officer sells $198k in stock - Investing.com
Under a trading plan, Tango Therapeutics (TNGX) officer Jessica Newcomb sold 8,200 shares in three transactions. - Stock Titan
Tango Therapeutics (TNGX) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
TNGX Stock Hits All-Time High – Wolfe Research Calls Tango Therapeutic’s Pancreatic Cancer Trial Data ‘Groundbreaking’ - Stocktwits
Top Odyssey Therapeutics (ODTX) Competitors 2026 - MarketBeat
How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% - Eastern Progress
Officer at Tango Therapeutics (NASDAQ: TNGX) to sell 15K shares - Stock Titan
CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $46 - moomoo.com
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report? - Yahoo Finance
Tango Therapeutics at cantor global healthcare: vopimetostat nears approval path - Investing.com India
TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits
Tango Therapeutics (TNGX) At 3.7x P B As Pullback Tests Whether It Looks Pricey - Yahoo Finance
Tango Therapeutics' R&D President Adam Crystal Executes Option Exercise and Sells 27,000 Shares Under Rule 10b5-1 Plan - Kalkine Media
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Insider at Tango Therapeutics (TNGX) sells 27,000 shares in preset plan - Stock Titan
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - Yahoo Finance
Tango (TNGX) Results Check: Available Metrics Are Broadly in Line in the Current Update; Market Response: Shares Move 2.64% Higher on the DayROE Trend Analysis - careplusvn.com
Farallon Capital Management Adds to Tango Therapeutics (TNGX) St - GuruFocus
Tango Therapeutics appoints Robert Azelby to Board of Directors - scanx.trade
HC Wainwright Issues Pessimistic Outlook for TNGX Earnings - MarketBeat
Research Analysts Issue Forecasts for TNGX Q2 Earnings - MarketBeat
Trv Gp Iv LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX - MarketBeat
Trv Gp Vi LLC Takes Position in Tango Therapeutics, Inc. $TNGX - MarketBeat
TANGO THERAPEUTICS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $68 FROM $66 - Bitget
The Bull Case For Tango Therapeutics (TNGX) Could Change Following $400M ATM Offering And Leadership Shift - simplywall.st
Tango (TNGX) Earnings Numbers in Focus: The Headline Comparisons Are Near Their Estimates in the Current Update; Market Read: Shares Finish 0.59% Up for the Current SessionEPS Growth Report - Vinanet
Tango Therapeutics (NASDAQ:TNGX) Given New $68.00 Price Target at HC Wainwright - MarketBeat
H.C. Wainwright raises Tango Therapeutics price target to $68 By Investing.com - Investing.com Canada
H.C. Wainwright raises Tango Therapeutics price target to $68 - Investing.com
Stifel Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Stifel reiterates Tango Therapeutics stock rating with $40 target - Investing.com
Stifel reiterates Tango Therapeutics stock rating with $40 target By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Early trial shows strong pancreatic cancer resp... - Pluang
Tango Therapeutics: Promising Early Data, But A Long Road Ahead - Seeking Alpha
Walleye Capital LLC Makes New Investment in Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics (NASDAQ:TNGX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Tango Therapeutics (TNGX) investors report 0% beneficial ownership in latest 13G/A - Stock Titan
Tango Therapeutics (TNGX): TCG Crossover and Chen Yu disclose 7% beneficial stake - Stock Titan
Goldman Sachs Group (TNGX) discloses 6.0% beneficial stake in Tango Therapeutics - Stock Titan
Woodline holds 4.0M Tango Therapeutics (TNGX) shares, a 2.5% stake - Stock Titan
Farallon group discloses 16.27M Tango Therapeutics (TNGX) shares and warrants - Stock Titan
Handelsbanken Fonder AB Acquires Shares of 287,900 Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics Insiders Selling US$727k In Stock Relieved As Market Cap Slides To US$4.4b - Moomoo
Tema ETFs LLC Buys New Holdings in Tango Therapeutics, Inc. $TNGX - MarketBeat
Tango Therapeutics (NASDAQ:TNGX): What Does the Latest Update Mean for Clinical Progress? - Kalkine Media
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Maze Therapeutics, Inc. (MAZE) and Xtant Medical Holdings (XTNT) - The Globe and Mail
Tango Therapeutics, Inc. (TNGX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tango Therapeutics Inc Azioni (TNGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):